Literature DB >> 7867619

Does mitogen-activated-protein kinase have a role in insulin action? The cases for and against.

R M Denton1, J M Tavaré.   

Abstract

The discovery of the mitogen-activated protein (MAP) kinase family of protein kinases has sparked off an intensive effort to elucidate their role in the regulation of many cellular processes. These protein kinases were originally identified based on their rapid activation by insulin. In this review we concentrate on examining the evidence for and against a role for the MAP kinases Erk-1 and Erk-2 in mediating the effects of insulin. While there is good evidence in favour of a direct role for MAP kinase in the growth-promoting effects of insulin and the regulation of Glut-1 and c-fos expression, and AP-1 transcriptional complex activity, this is by no means conclusive. MAP kinase may also play a role in the control of mRNA translation by insulin. On the other hand, the evidence suggests that MAP kinase is not sufficient for the acute regulation of glucose transport (Glut-4 translocation), glycogen synthesis, acetyl-CoA carboxylase or pyruvate dehydrogenase activity. The findings suggest that insulin may utilise at least three distinct signalling pathways which do not involve MAP kinase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7867619     DOI: 10.1111/j.1432-1033.1995.tb20179.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  17 in total

Review 1.  Cellular and molecular regulation of cardiac glucose transport.

Authors:  L H Young; D L Coven; R R Russell
Journal:  J Nucl Cardiol       Date:  2000 May-Jun       Impact factor: 5.952

2.  Effects of bis(maltolato) oxovanadium (IV) on protein serine kinases in skeletal muscle of streptozotocin-diabetic rats.

Authors:  S Bhanot; J Girn; P Poucheret; J H McNeill
Journal:  Mol Cell Biochem       Date:  1999-12       Impact factor: 3.396

Review 3.  Insulin signal transduction through protein kinase cascades.

Authors:  J Avruch
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

Review 4.  Binding of SH2 containing proteins to the insulin receptor: a new way for modulating insulin signalling.

Authors:  F Liu; R A Roth
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

5.  Biosynthesis of the endogenous cyclic adenosine monophosphate (AMP) antagonist, prostaglandylinositol cyclic phosphate (cyclic PIP), from prostaglandin E and activated inositol polyphosphate in rat liver plasma membranes.

Authors:  H K Wasner; M Lessmann; M Conrad; H Amini; E Psarakis; A Mir-Mohammad-Sadegh
Journal:  Acta Diabetol       Date:  1996-07       Impact factor: 4.280

Review 6.  Molecular mechanisms for the control of translation by insulin.

Authors:  C G Proud; R M Denton
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

7.  Stimulation of C2C12 myoblast growth by basic fibroblast growth factor and insulin-like growth factor 1 can occur via mitogen-activated protein kinase-dependent and -independent pathways.

Authors:  D J Milasincic; M R Calera; S R Farmer; P F Pilch
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

8.  A role for heterotrimeric GTP-binding proteins and ERK1/2 in insulin-mediated, nitric-oxide-dependent, cyclic GMP production in human umbilical vein endothelial cells.

Authors:  O Konopatskaya; A C Shore; J E Tooke; J L Whatmore
Journal:  Diabetologia       Date:  2005-03-01       Impact factor: 10.122

9.  Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy.

Authors:  Siva Bhashyam; Anjali V Fields; Brandy Patterson; Jeffrey M Testani; Li Chen; You-Tang Shen; Richard P Shannon
Journal:  Circ Heart Fail       Date:  2010-05-13       Impact factor: 8.790

10.  A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies.

Authors:  K Almind; G Inoue; O Pedersen; C R Kahn
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.